Related Targets |
Target |
Mechanism EGFRvIII antagonists [+2] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism MSLN inhibitors [+2] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism MSLN inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Mar 2024 |
Sponsor / Collaborator A2 Biotherapeutics, Inc.Startup [+1] |
Start Date05 Feb 2024 |
Sponsor / Collaborator |
Start Date31 Jan 2024 |
Sponsor / Collaborator |